Drug shown to reverse radioiodine resistance in some advanced thyroid cancers (EurekAlert, 14 February 2013)
EJE goes mobile

Merck shares fall on worries about osteoporosis drug (Reuters, 1 February 2013)

13 Feb 2013

Merck has announced that it will delay seeking approval from the U.S. Food and Drug Administration for its cathepsin K inhibitor odanacatib until next year.

Full article

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read